Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN).

Full DD Report for BHVN

You must become a subscriber to view this report.


Recent News from (NYSE: BHVN)

Your Daily Pharma Scoop: Biohaven Updates, MEIP Offering, Kite European Expansions
Analysis focus: BHVN Biohaven Pharmaceuticals (BHVN) is a CNS-focused company with a strong pipeline with multiple drug candidates in late stage trials. The company recently announced a number of updates for its pipeline. For its lead candidate, rimegepant from the CGRP receptor antagoni...
Source: SeekingAlpha
Date: May, 17 2018 00:16
Biohaven Pharmaceuticals misses by $1.18
Biohaven Pharmaceuticals (NYSE: BHVN ): Q1 EPS of -$2.32 misses by $1.18 . Cash and equivalents of $104.2M Press Release More news on: Biohaven Pharmaceutical Holding Company Ltd., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: May, 15 2018 16:43
Biohaven Pharma announces key milestones for 2018
In its Q1 report, Biohaven Pharmaceutical (NYSE: BHVN ) announces the following key future events for the year: More news on: Biohaven Pharmaceutical Holding Company Ltd., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 15 2018 16:35
Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results
NEW HAVEN, Conn. , May 15, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological disorders, including rare disorders, reported finan...
Source: PR Newswire
Date: May, 15 2018 16:15
Oryzon Genomics commences mid-stage study of Alzheimer's candidate
Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, ...
Source: SeekingAlpha
Date: May, 14 2018 12:27
Institutional Top Ideas Series: Ra Capital Management
In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su...
Source: SeekingAlpha
Date: May, 10 2018 02:04
Our Free Research Report on Biogen and More Biotech Stocks
Stock Research Monitor: AVXS, BHVN, and BMRN LONDON, UK / ACCESSWIRE / May 9, 2018 / If you want a free Stock Review on BIIB sign up now at www.wallstequities.com/registration . On Tuesday, May 08, 2018, US markets saw four out of nine sectors finishing the day in green, four in re...
Source: ACCESSWIRE IA
Date: May, 09 2018 07:35
Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS)
NEW HAVEN, Conn. , May 9, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it has established an expanded access program (EAP) with sublingual BHV-0223, an investigational drug candidate, for patients with amyotrophic lateral scleros...
Source: PR Newswire
Date: May, 09 2018 03:00
Allergan Hits Another Home Run For 2nd Migraine Study
Recently, Allergan ( AGN ) announced positive results from its second phase 3 study treating patients with acute migraine. The company used its drug ubrogepant to treat these patients. This is highly positive, because now it has all it needs to file an NDA to the FDA by 2019. That's why I be...
Source: SeekingAlpha
Date: April, 30 2018 04:22
Your Daily Pharma Scoop: Roche's Ocrevus, Biogen Data, Biohaven Update
Analysis focus: Roche Today we will discuss Roche (RHHBY), after the company announced data with its multiple sclerosis ((MS)) treatment Ocrevus from a long-term extension study. Ocrevus has seen strong uptake since its launch last year, and is expected to be a key value driver...
Source: SeekingAlpha
Date: April, 24 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1729.87530.2930.7429.41312,372

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1461086970.1956Short
2018-08-139184,93518.6018Cover
2018-08-104101,35330.3030Cover
2018-08-097191,75041.0857Short
2018-08-0813,55513,95697.1267Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BHVN.


About Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN)

Logo for Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NYSE: BHVN)

      Prospectus filed under Rule 424(b)(3)
      Filing Type: 424B3Filing Source: edgar
      Filing Date: May, 16 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 15 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: May, 11 2018
      Notice from the SEC of registration effectiveness
      Filing Type: EFFECTFiling Source: edgar
      Filing Date: April, 05 2018
      General form for registration of securities under the Securities Act of 1933
      Filing Type: S-1Filing Source: edgar
      Filing Date: April, 03 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: March, 29 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 26 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 12 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 09 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 06 2018

       

       


      Daily Technical Chart for (NYSE: BHVN)

      Daily Technical Chart for (NYSE: BHVN)


      Stay tuned for daily updates and more on (NYSE: BHVN)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NYSE: BHVN)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BHVN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of BHVN and does not buy, sell, or trade any shares of BHVN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/